Fig. 7

TC2N represses FASN-driven tumor progression and its high expression in BC indicate low fatty deposition and good prognosis. A WB analysis of TC2N and FASN expression in stable M231, MCF7 and SKBR3 cells with 0.2 μM TVB-3166 treatment (Upper). Transwell assays were used to examine the effect of FASN ablation on cell migration and invasion of BC stable cells (Under). The P value was measured with Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001. B CD133⁺ analysis was used to examine the effect of FASN ablation on stemness of BC stable cell spheres. Mean ± SEM (n = 3). The P value was measured with Student’s t-tests. ***P < 0.001. C ALDH⁺ analysis was used to examine the effect of FASN ablation on stemness of BC stable cells. Mean ± SEM (n = 3). The P value was measured with Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001. D The fatty deposits were detected by oil red O staining in tumor tissues of BC patients. Scale bar represent 100 μm. E and F Survivorship curves showed that the overall survival rates of BC patients with high or low levels of FASN and of those with low expression of TC2N and high expression of FASN or high expression of TC2N and low expression of FASN. The high or low levels of TC2N and FASN were defined by their median levels in the BC